NWPF

News ArchivesRead News

New Experiments Target Parkinson's

Friday October 25, 2013

Carolyn Y. Johnson

The Boston Globe - A team of scientists at the Cambridge-based Whitehead Institute for Biomedical Research have identified a compound that can reverse some of the toxicity that occurs in brain cells created from Parkinson’s disease patients’ stem cells.

The work, described in a pair of studies published Thursday in the journal Science, is still very early — the researchers aren’t even using the word “drug” when describing the small molecule that jumped out when they screened a chemical library of about 200,000 compounds. But the methods they used demonstrate the power of an approach that knits together multiple basic biology technologies.

Similar experiments may now be used to aid drug development efforts in a wide variety of neurodegenerative diseases, including ALS (Lou Gehrig’s disease) and Alzheimer’s.

“It’s a very nice piece of work — an elegant demonstration of bridging basic yeast screens to cells that are directly relevant to the human condition,” said Dr. Dennis Selkoe, professor of neurologic diseases at Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the studies. “The drug in question did interesting things, but is still a long way from being converted into a medicine that people can take.”

The work in Susan Lindquist’s laboratory at the Whitehead grew out of her ongoing efforts to utilize the humble Baker’s yeast to model complex neurodegenerative diseases. The researchers engineered the yeast to overproduce alpha-synuclein, a protein that forms toxic clumps in the brains of Parkinson’s patients.

Similar to human brain cells, yeast were sickened when the protein formed clusters. The researchers then looked for compounds that were able to reverse the problems. A few seemed promising, but one in particular appeared to affect the way the cells cleared out the alpha-synuclein clusters.

Researchers collected cells from patients with an aggressive, genetic form of Parkinson’s samples and used a technique that won the Nobel prize in 2012 to create stem cells. From the stem cells, they created the neurons that are afflicted in Parkinson’s and tested the compound, finding it could reverse signs of pathology.

Johnson, C.Y. (25 Oct. 2013). The Boston Globe. New Experiments Target Parkinson's. www.bostonglobe.com.

Recent News

May 20 - Book Review: Aging in the Key of Humor
May 19 - Press Release: The Michael J. Fox Foundation for Parkinson's Research Joins Multinational Critical Path for Parkinson's Consortium
May 19 - Congress reaches deal to overhaul chemical regulation
May 16 - Lifestyle: Why Parkinson's disease won't stop me rowing across the Pacific
May 16 - Many biomarkers for PD fail to inform on progression
May 10 - Parkinson's Cell Transplant Shows Good Reinnervation at 24 Years
May 7 - Growing art installation gathers stories of living with Parkinson's
May 5 - New technique can provide better cell transplants against Parkinson's disease
May 2 - What's Good For The Heart Is Good For The Brain
Apr 29 - Press Release: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease
Apr 28 - Dopamine-making neurons can be chemically controlled in animal model of Parkinson's
Apr 25 - Lifestyle: Dating with Disease
Apr 25 - Scientific breakthrough in fight against Parkinson's and Alzheimer's
Apr 20 - Breakthrough Parkinson's disease blood test
Apr 15 - Living with Parkinson's
Apr 12 - Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease
Apr 11 - Yoga for Every Body: Experts say yoga can ease pain and improve mobility for people with neurologic conditions
Apr 9 - Commonly prescribed Parkinson's drugs up risk of compulsive gambling, shopping, binge eating, hypersexuality
Apr 7 - Pfizer and IBM Launch Innovative Research Project to Transform Parkinson's Disease Care
Apr 7 - Parkinson's Drug Highly Effective for Resistant Depression